Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

This study has been completed.
Sponsor:
Collaborators:
Cardiovascular Cell Therapy Research Network (CCTRN)
Information provided by (Responsible Party):
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00824005
First received: January 15, 2009
Last updated: April 2, 2013
Last verified: April 2013
  Purpose

Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments. One new treatment approach uses stem cells—specialized cells capable of developing into other types of cells—to stimulate growth of new blood vessels for the heart. This study will determine the safety and effectiveness of withdrawing stem cells from someone's bone marrow and injecting those cells into the person's heart as a way of treating people with CAD and heart failure.


Condition Intervention Phase
Chronic Ischemic Heart Disease
Left Ventricular Dysfunction
Angina
Ischemic Cardiomyopathy
Biological: Adult stem cells
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Change in Maximal Oxygen Consumption (VO2max) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    The VO2(max) is assessed using the Naughton treadmill protocol.

  • Change in Left Ventricular End Systolic Volume (LVESV)as Assessed Via Echo [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Echocardiographic measurements were performed by an echocardiographic core laboratory. LVESVs were calculated by the modified biplane Simpson method, using myocardial contrast to enhance endocardial definition. To account for patient body surface area, LVESV indices are reported.

  • Change in Reversible Defect Size [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Adenosine myocardial perfusion (SPECT) tests were collected at baseline and 6 months to identify change in ischemic (reversible) defects. SPECT imaging was performed at rest and after adenosine infusion over 4 minutes. To enhance the detection of viability on resting images, sublingual nitroglycerin was administered 15 minutes before injecting technetium Tc 99m sestamibi for the resting image.


Secondary Outcome Measures:
  • Regional Wall Motion by MRI (in Eligible Patients) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Regional wall motion as measured by cardiac MRI (in patients who are not contraindicated)

  • Regional Blood Flow Improvement by MRI (in Eligible Patients) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Regional blood flow improvement as measured by cardiac MRI (in patients who are not contraindicated)

  • Regional Wall Motion by Echocardiography [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Movement of the left ventricular wall measured in mm from baseline to six months.

  • Clinical Improvement in CCS Classification (Angina Pectoris) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Clinical improvement in Canadian Cardiovascular Society (CCS) functional classification of angina pectoris. The CCS scale ranges from Class I (best)"able to conduct ordinary daily activity without causing angina" to Class IV (worst) "Inability to perform any physical activity without discomfort; anginal symptoms may be present at rest." Patients receive a rating of 1-4 for their anginal symptoms. Results reflect the mean change in the total score over time.

  • Clinical Improvement in NYHA Classification [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Clinical improvement in New York Heart Association (NYHA) classification. The NYHA scale ranges from 1 (best)"Mild- no limitation of physical activity due to heart failure" to 4 (worst) "Severe-Unable to carry out any physical activity without discomfort due to heart failure". Patients receive a rating of 1-4 for their heart failure symptoms. Results reflect the mean change in the total score over time.

  • Number of Participants With a Decrease in Anti-anginal Medication [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Number of participants with a decrease in anti-anginal medication (nitrates needed weekly)

  • Exercise Time and Level [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Exercise time and level as assessed via six minute walk test. (change in number of feet walked)

  • Serum BNP Levels in Patients With CHF [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Serum b-type natriuretic peptide (BNP) levels in patients with congestive heart failure (CHF). A minority number of patients had pro-BNP collected versus regular BNP; these numbers are reported in the analysis population description.

  • LV Diastolic Dimension [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular (LV) diastolic dimension as assessed by contrast echocardiography

  • Incidence of a Major Adverse Cardiac Event [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: Yes ]

    Incidence of major adverse cardiac events (new MI, rehospitalization for PCI in coronary artery territories that were treated, death, or rehospitalization for acute coronary syndrome and for congestive heart failure).

    (Incidence rate)


  • Reduction in Fixed Perfusion Defect(s)Via SPECT [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Fixed total defect is the stress total defect minus the reversible component.


Enrollment: 92
Study Start Date: March 2009
Study Completion Date: May 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Injections
Participants will receive placebo injections.
Biological: Placebo
Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
Other Names:
  • Human serum albumin
  • HSA
Experimental: Active Stem Cell Injections
Participants will receive active stem cell injections.
Biological: Adult stem cells
Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
Other Names:
  • Adult autologous stem cells
  • Bone marrow mononucleated cells

Detailed Description:

Coronary artery disease (CAD), a disease in which blood vessels become clogged by a build-up of plaque, is the leading cause of heart failure, a condition in which the heart can no longer pump enough blood to the rest of the body. People with heart failure caused by CAD are said to have ischemic cardiomyopathy. Normal treatment for CAD involves coronary artery bypass grafting (in which a vein from another part of the body is grafted around an artery that has become blocked) or coronary angioplasty and stent placement (in which a blocked artery is opened and a small tube is placed to keep the artery open). However, some people with ischemic cardiomyopathy, such as those with substantial scar tissue on the heart wall or those with a particular heart structure, may not be eligible for these treatments. An alternative treatment being developed is therapeutic angiogenesis, which involves stimulating the growth of new blood vessels. Recent research has shown that withdrawing stem cells from bone marrow and implanting the cells into heart tissue may be an effective way to achieve therapeutic angiogenesis. This study will determine the safety and effectiveness of using stem cells to stimulate new blood vessel growth in the hearts of people with ischemic cardiomyopathy.

Participation in this study, including follow-up visits and phone calls, will last 60 months. Participants will first undergo 3 to 4 days of screening procedures that will include a physical examination, multiple lab tests, and a battery of tests on heart health. Next, participants will be randomized to receive either active stem cell injections or placebo injections. The injections and related procedures will be performed in a hospital and last approximately 72 hours. During this time, participants in both groups will first undergo a bone marrow aspiration procedure. Participants receiving active stem cells will also undergo NOGA electromechanical cardiac mapping, which involves inserting a monitoring device through a catheter and into the heart. Injections of stem cells will then be made to 15 damaged sites on the heart through a special catheter. Participants receiving placebo injections will receive 15 injections of an inactive, saline-based solution. After the injection procedures, all participants will undergo two echocardiograms, an electrocardiogram, blood tests, and overnight monitoring in a telemetry unit.

After the hospital stay, all participants will attend five study visits that will occur 1 week and 1, 3, 6, and 12 months after the injection procedures. At all study visits, participants will undergo an electrocardiogram, lab tests, and a review of adverse health events. On all but the last study visit, participants will have cardiac markers assessed, and they will wear a 24-hour Holter monitor to track heart activity. At the last three visits, participants will also complete quality of life questionnaires. All participants will then receive four follow-up telephone calls that will occur 2, 3, 4, and 5 years after the injection procedures.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients >18 years of age with significant coronary heart disease not amenable to revascularization.
  • Left ventricular dysfunction (LVEF) less than or equal to 45%, measured by echocardiogram; limiting angina (Class II to IV); and/or congestive heart failure (CHF), NYHA class II to III
  • Receiving maximal medical therapy, defined as a medical regimen that includes the maximal tolerated dose of at least two antiangina medications, such as beta-blockers, nitrates, or calcium-channel blockers
  • Presence of a defect, as identified by single photon emission computed tomography (SPECT) isotope protocol, or viability, as identified by NOGA electromechanical cardiac mapping system
  • Coronary artery disease not well suited to any other type of revascularization procedure in the target region of the ventricle, as determined by a cardiovascular surgeon and interventional cardiologist who are not investigators in the trial
  • Hemodynamic stability, as defined by systolic blood pressure of at least 80 mm Hg without intravenous pressors or support devices
  • Females of childbearing potential must be willing to use two forms of birth control for the duration of the study

Exclusion Criteria:

  • Atrial fibrillation or flutter without a pacemaker that guarantees a stable heart rate
  • Unstable angina
  • Left ventricular (LV) thrombus, as documented by echocardiography or LV angiography
  • A vascular anatomy that precludes cardiac catheterization
  • Severe valvular disease or mechanical aortic valve that precludes safe entry of the catheter into the left ventricle
  • Pregnant or lactating
  • Platelet count less than 100,000 per mm3
  • White blood cell count less than 2,000 per mm3
  • Revascularization within 30 days of consent
  • Transient ischemic attack or stroke within 60 days of study consent
  • Implantable cardioverter-defibrillator shock within 30 days of baseline consent, and within 30 days of randomization
  • Presence of ventricular tachycardia lasting 30 seconds or more on 24-hour Holter monitor or electrocardiogram (ECG) performed during screening period
  • Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in the absence of warfarin therapy
  • A history of malignancy in the last 5 years excluding basal cell carcinoma, that has been surgically removed, with proof of surgical clean margins
  • Has a known history of HIV, has active hepatitis B or active hepatitis C
  • Any condition requiring immunosuppressive medication
  • High-risk acute coronary syndrome (ACS) or a myocardial infarction in the month prior to consent
  • A left ventricular wall thickness of <8 mm (by echocardiogram) of the infero-lateral wall at the target site for cell injection.
  • Inability to walk on a treadmill, except for class IV angina patients, who will be evaluated separately
  • Enrolled in an investigational device or drug study within the previous 30 days
  • Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to study entry
  • Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5 mg/dL or requiring dialysis
  • Any other condition that in the judgment of the investigator would be a contraindication to enrollment or follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824005

Locations
United States, Florida
University of Florida-Department of Medicine
Gainesville, Florida, United States, 32611
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77225
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Cardiovascular Cell Therapy Research Network (CCTRN)
Investigators
Study Chair: Robert Simari, MD Cardiovascular Cell Therapy Research Network
  More Information

Additional Information:
Publications:
Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24.

Responsible Party: Dr Lemuel A Moye III, Professor - School of Public Health, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00824005     History of Changes
Other Study ID Numbers: 580, U01HL087318, 1 U01-HL-087318-01 (Project 3)
Study First Received: January 15, 2009
Results First Received: August 30, 2012
Last Updated: April 2, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center, Houston:
Congestive Heart Failure
Regional Wall Motion
Perfusion Defects

Additional relevant MeSH terms:
Cardiomyopathies
Coronary Artery Disease
Heart Diseases
Ischemia
Myocardial Ischemia
Ventricular Dysfunction
Ventricular Dysfunction, Left
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Coronary Disease
Pathologic Processes
Vascular Diseases
Albunex
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 23, 2014